CTRI/2018/10/015978尚未招募1 期
A pilot study to assess the effectiveness and safety of oral vitmain D versus low dose oral acitretin in congenital non syndromic ichthyosis
Department of Dermatology Venereology and Leprology0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Non syndromic congenital ichthyosis patients regardless of age and sex.
- •2.Women of child bearing potential if using adequate contraception.
- •3.Patients with either normal vitamin D levels or low vitamin D levels not having any clinical or radiological manifestations of rickets.
- •4.Patients who can give valid consent.
- •5.Willing for monthly follow-up visits for at least 6 months.
排除标准
- •1.Ichthyosis vulgaris
- •2.XLRI involving less than 10% body surface area.
- •3.Pregnant and lactating mothers.
- •4.Systemic treatment within 4 weeks prior to the start of treatment phase.
- •5.Patients with hypercalcemia or high vitamin D, and significant renal or hepatic disease.
- •6.Patients with severe hypovitaminosis D affecting bone health as assessed clinically and radiologically.
- •7.Inability to come for monthly follow up visits for 6 months
- •8.Those who cannot provide consent for the study
研究者
相似试验
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.EUCTR2007-004337-41-FRGENFIT30
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.patients presenting with impaired glucose tolerance and abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10036481Term: Pre-diabetesMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2009-011003-23-FRGENFIT40
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.Atherogenic dyslipidaemic patients with abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10058108Term: DyslipidaemiaMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2008-005779-86-FRGENFIT90
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.EUCTR2007-003237-16-FRGENFIT30
进行中（未招募）
不适用
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 12 weeks in patients with Type 2 Diabetes mellitus.A Multicentre, Randomised, Double Blind, Placebo-Controlled study.EUCTR2010-021986-60-LVGENFIT120